Larimar Therapeutics, Inc.
Financials
Valuation Metrics
Larimar Therapeutics, Inc.'s Market Cap is $394M. At end of 2025 it was $325M. Ranked #2879 of 3,121 in US market (top 92%), #1280 of 1,463 on NASDAQ (top 87%), #232 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $394M | US#2,879/3,121 Sec#232/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-173M | US—/3,121 Sec—/266 |
| Total Assets | $165M | US#3,022/3,121 Sec#253/266 |
| Net Assets | $127M | US#2,778/3,121 Sec#211/266 |
| Employees | 71 | US#2,677/3,121 Sec#196/266 |
| Value | ||
| P/B | 3.09x | US#1,782/3,121 Sec#87/266 |
| FCF Yield | -39.64% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -135.50% | US#2,820/3,121 Sec#211/266 |
| Financial Health | ||
| Debt Ratio | 29.77% | US#333/3,121 Sec#104/266 |
| Total Debt | $5M | US#2,910/3,121 Sec#218/266 |
| FCF | $-156M | US#2,726/3,121 Sec#180/266 |
| Cash | $93M | US#2,274/3,121 Sec#183/266 |
| Current Ratio | 4.70x | US#512/3,121 Sec#155/266 |
| Performance | ||
| 1Y Return | -11.45% | US#2,022/3,121 Sec#195/266 |
| 1M Return | -10.82% | US#1,964/3,121 Sec#154/266 |
| From 52W High | -40.97% | US#2,482/3,121 Sec#196/266 |
| 1Y MDD | -48.74% | US#2,410/3,121 Sec#175/266 |
| Trading | ||
| Volume | 1,501,319 shares | US#1,248/3,121 Sec#132/266 |
| Trading Value | $6M | US#2,688/3,121 Sec#226/266 |
| Per Share | ||
| EPS | $-1.66 | US—/3,121 Sec—/266 |
| BPS | $1.23 | US#2,667/3,121 Sec#197/266 |
Company Info
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.